<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_agents" title="Recent Advances in the Discovery of Novel Antiprotozoal Agents" shortTitle="agents" author="Seong-Min Lee, Min-Sun Kim, Faisal Hayat, Dongyun Shin" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/1420-3049/24/21/3886/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
2.	LS	2.
Recent	JJ	Recent
Progress	NNP	Progress
of	IN	of
Antiprotozoan	NNP	Antiprotozoan
Agents	NNPS	agent
</s>
</head>
<head>
<s type="frag">
2.1.	CD	2.1.
Anti-Giardiasis	NNP	Anti-Giardiasis
</s>
</head>
<p>
<s type="decl">
Giardiasis	NNP	Giardiasis
is	VBZ	be
caused	VBN	cause
by	IN	by
the	DT	the
protozoan	NN	protozoan
parasite	NN	parasite
<hi rend="italic">
G.	NNP	G.
intestinalis	NN	intestinali
</hi>
(	-LRB-	(
also	RB	also
known	VBN	know
as	IN	as
<hi rend="italic">
G.	NNP	G.
lamblia	NNP	lamblia
</hi>
or	CC	or
<hi rend="italic">
G.	NNP	G.
duodenalis	NNP	duodenalis
</hi>
)	-RRB-	)
.	.	.
</s>
<s type="decl">
It	PRP	it
is	VBZ	be
also	RB	also
known	VBN	know
by	IN	by
the	DT	the
common	JJ	common
name	NN	name
“	``	''
beaver	NN	beaver
fever	NN	fever
,	,	,
”	''	''
because	IN	because
this	DT	this
infection	NN	infection
was	VBD	be
reported	VBN	report
in	IN	in
campers	NNS	camper
who	WP	who
drank	VBD	drank
contaminated	VBN	contaminate
water	NN	water
that	WDT	that
was	VBD	be
inhabited	VBN	inhabit
by	IN	by
beavers	NNS	beaver
.	.	.
</s>
<s type="decl">
Giardiasis	NNP	Giardiasis
is	VBZ	be
the	DT	the
most	RBS	most
common	JJ	common
protozoan	JJ	protozoan
infection	NN	infection
in	IN	in
human	JJ	human
beings	NNS	being
,	,	,
and	CC	and
it	PRP	it
occurs	VBZ	occur
in	IN	in
both	CC	both
developing	VBG	develop
and	CC	and
industrialized	VBN	industrialize
countries	NNS	country
.	.	.
</s>
<s type="decl">
Its	PRP$	its
global	JJ	global
incidence	NN	incidence
is	VBZ	be
believed	VBN	believe
to	TO	to
range	VB	range
between	IN	between
20	CD	20
%	NN	%
–	SYM	-
60	CD	60
%	NN	%
,	,	,
with	IN	with
2	CD	2
%	NN	%
–	SYM	-
7	CD	7
%	NN	%
incidence	NN	incidence
in	IN	in
industrialized	VBN	industrialize
nations	NNS	nation
.	.	.
</s>
<s type="decl">
<hi rend="italic">
Giardia	NNP	Giardia
intestinalis	NN	intestinali
</hi>
was	VBD	be
first	RB	first
described	VBN	describe
in	IN	in
<date when="1681">
1681	CD	1681
</date>
after	IN	after
the	DT	the
Dutch	JJ	Dutch
microscopist	NN	microscopist
Antonie	NNP	Antonie
van	NNP	van
Leeuwenhoek	NNP	Leeuwenhoek
observed	VBD	observe
the	DT	the
protozoan	NN	protozoan
in	IN	in
his	PRP$	his
own	JJ	own
diarrheic	JJ	diarrheic
stools	NNS	stool
.	.	.
</s>
<s type="decl">
This	DT	this
disease	NN	disease
is	VBZ	be
often	RB	often
prevalent	JJ	prevalent
in	IN	in
poor	JJ	poor
countries	NNS	country
and	CC	and
communities	NNS	community
that	WDT	that
have	VBP	have
untreated	JJ	untreated
water	NN	water
,	,	,
inadequate	JJ	inadequate
sanitation	NN	sanitation
,	,	,
and	CC	and
poor	JJ	poor
dietary	NN	dietary
status	NN	status
.	.	.
</s>
<s type="decl">
The	DT	the
infection	NN	infection
is	VBZ	be
caused	VBN	cause
by	IN	by
fecal	NN	fecal
–	SYM	-
oral	JJ	oral
transmission	NN	transmission
and	CC	and
initiated	VBN	initiate
by	IN	by
the	DT	the
ingestion	NN	ingestion
of	IN	of
infectious	JJ	infectious
cysts	NNS	cyst
from	IN	from
contaminated	VBN	contaminate
water	NN	water
or	CC	or
through	IN	through
person-to-person	JJ	person-to-person
contact	NN	contact
.	.	.
</s>
<s type="decl">
After	IN	after
excystation	NN	excystation
,	,	,
flagellated	VBN	flagelate
trophozoites	NNS	trophozoite
colonize	VBP	colonize
the	DT	the
upper	JJ	upper
small	JJ	small
intestine	NN	intestine
,	,	,
where	WRB	where
they	PRP	they
attach	VBP	attach
to	IN	to
the	DT	the
epithelial	JJ	epithelial
lining	NN	lining
but	CC	but
do	VBP	do
not	RB	not
invade	VB	invade
the	DT	the
mucosa	NN	mucosa
.	.	.
</s>
<s type="decl">
The	DT	the
duration	NN	duration
of	IN	of
Giardia	NNP	Giardia
infection	NN	infection
is	VBZ	be
variable	JJ	variable
;	:	;
however	RB	however
,	,	,
chronic	JJ	chronic
infection	NN	infection
and	CC	and
reinfection	NN	reinfection
commonly	RB	commonly
occur	VBP	occur
.	.	.
</s>
<s type="decl">
Approximately	RB	approximately
50	CD	50
%	NN	%
of	IN	of
the	DT	the
symptoms	NNS	symptom
classically	RB	classically
associated	VBN	associate
with	IN	with
giardiasis	NN	giardiasis
are	VBP	be
asymptomatic	JJ	asymptomatic
including	VBG	include
diarrhea	NN	diarrhea
,	,	,
abdominal	JJ	abdominal
pain	NN	pain
,	,	,
nausea	NN	nausea
,	,	,
vomiting	NN	vomiting
,	,	,
and	CC	and
anorexia	NN	anorexia
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
infected	VBN	infect
individuals	NNS	individual
can	MD	can
also	RB	also
develop	VB	develop
extraintestinal	JJ	extraintestinal
and	CC	and
postinfectious	JJ	postinfectious
complications	NNS	complication
.	.	.
</s>
<s type="decl">
Chronic	JJ	Chronic
extraintestinal	JJ	extraintestinal
sequelae	NN	sequelae
may	MD	may
affect	VB	affect
the	DT	the
joints	NNS	joint
,	,	,
skin	NN	skin
,	,	,
eyes	NNS	eye
,	,	,
and	CC	and
central	JJ	central
nervous	JJ	nervous
system	NN	system
,	,	,
but	CC	but
the	DT	the
underlying	JJ	underlie
mechanisms	NNS	mechanism
are	VBP	be
unknown	JJ	unknown
.	.	.
</s>
<s type="decl">
According	VBG	accord
to	IN	to
research	NN	research
data	NNS	datum
,	,	,
Giardia	NNP	Giardia
has	VBZ	have
eight	CD	8
distinct	JJ	distinct
genetic	JJ	genetic
assemblages	NNS	assemblage
labelled	VBN	label
as	IN	as
assemblage	NN	assemblage
“	``	''
A	CD	a
”	''	''
through	IN	through
“	``	''
H	NN	H
”	''	''
,	,	,
and	CC	and
assemblages	NNS	assemblage
“	``	''
A	CD	a
”	''	''
and	CC	and
“	``	''
B	NN	B
”	''	''
are	VBP	be
responsible	JJ	responsible
for	IN	for
infection	NN	infection
in	IN	in
humans	NNS	human
.	.	.
</s>
</p>
<p>
<s type="decl">
Three	CD	3
classes	NNS	class
of	IN	of
drugs	NNS	drug
are	VBP	be
currently	RB	currently
used	VBN	use
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
giardiasis	NN	giardiasis
:	:	:
metronidazole	NN	metronidazole
,	,	,
mepacrine	NN	mepacrine
analogs	NNS	analog
,	,	,
and	CC	and
nitrofurans	NNS	nitrofuran
,	,	,
such	JJ	such
as	IN	as
furazolidone	NN	furazolidone
(	:	(
</s>
<figure>
<s type="frag">
Figure	NNP	Figure
1	CD	1
</s>
</figure>
<s type="frag">
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Metronidazole	NNP	Metronidazole
is	VBZ	be
the	DT	the
most	RBS	most
widely	RB	widely
used	VBN	use
drug	NN	drug
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
giardiasis	NN	giardiasis
globally	RB	globally
and	CC	and
it	PRP	it
is	VBZ	be
generally	RB	generally
effective	JJ	effective
and	CC	and
well-tolerated	JJ	well-tolerated
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
the	DT	the
United	NNP	Unite
States	NNPS	State
Food	NNP	Food
and	CC	and
Drug	NNP	Drug
Administration	NNP	Administration
(	-LRB-	(
FDA	NNP	FDA
)	-RRB-	)
has	VBZ	have
not	RB	not
yet	RB	yet
approved	VBN	approve
this	DT	this
drug	NN	drug
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
Giardia	NNP	Giardia
infection	NN	infection
because	IN	because
of	IN	of
its	PRP$	its
toxicity	NN	toxicity
and	CC	and
major	JJ	major
side	NN	side
effects	NNS	effect
,	,	,
such	JJ	such
as	IN	as
seizures	NNS	seizure
,	,	,
ataxia	NN	ataxia
,	,	,
peripheral	JJ	peripheral
neuropathy	NN	neuropathy
,	,	,
transient	JJ	transient
myopia	NN	myopia
,	,	,
gastric	JJ	gastric
mucosal	JJ	mucosal
irritation	NN	irritation
,	,	,
sperm	NN	sperm
damage	NN	damage
,	,	,
and	CC	and
hematuria	NN	hematuria
.	.	.
</s>
<s type="decl">
Tinidazole	NNP	Tinidazole
is	VBZ	be
an	DT	a
N1-position	NNP	N1-position
modified	VBN	modify
5-nitro	NN	5-nitro
imidazole	NN	imidazole
,	,	,
which	WDT	which
has	VBZ	have
been	VBN	be
approved	VBN	approve
by	IN	by
the	DT	the
FDA	NNP	FDA
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
giardiasis	NN	giardiasis
.	.	.
</s>
<s type="decl">
Nitazoxanide	NNP	Nitazoxanide
(	-LRB-	(
NTZ	NNP	NTZ
)	-RRB-	)
belongs	VBZ	belong
to	IN	to
an	DT	a
emerging	VBG	emerge
class	NN	class
of	IN	of
5-nitrothiazole	JJ	5-nitrothiazole
compounds	NNS	compound
with	IN	with
potential	JJ	potential
antigiardial	JJ	antigiardial
activity	NN	activity
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
although	IN	although
NTZ	NNP	NTZ
is	VBZ	be
generally	RB	generally
well	RB	well
tolerated	VBN	tolerate
,	,	,
some	DT	some
adverse	JJ	adverse
effects	NNS	effect
such	JJ	such
as	IN	as
abdominal	JJ	abdominal
pain	NN	pain
,	,	,
diarrhea	NN	diarrhea
,	,	,
and	CC	and
nausea	NN	nausea
limit	VBP	limit
the	DT	the
safe	JJ	safe
use	NN	use
for	IN	for
human	JJ	human
beings	NNS	being
.	.	.
</s>
<s type="decl">
Mepacrine	NNP	Mepacrine
is	VBZ	be
no	RB	no
longer	RBR	long
available	JJ	available
in	IN	in
the	DT	the
United	NNP	Unite
States	NNPS	State
,	,	,
and	CC	and
it	PRP	it
is	VBZ	be
being	VBG	be
replaced	VBN	replace
in	IN	in
most	JJS	most
of	IN	of
its	PRP$	its
applications	NNS	application
with	IN	with
safer	JJR	safe
and	CC	and
more	RBR	more
specific	JJ	specific
drugs	NNS	drug
.	.	.
</s>
<s type="decl">
Furazolidone	NNP	Furazolidone
also	RB	also
has	VBZ	have
serious	JJ	serious
side	NN	side
effects	NNS	effect
,	,	,
such	JJ	such
as	IN	as
gastrointestinal	JJ	gastrointestinal
disturbances	NNS	disturbance
,	,	,
hemolytic	JJ	hemolytic
anemia	NN	anemia
,	,	,
disulfiram-like	JJ	disulfiram-like
reactions	NNS	reaction
to	IN	to
alcohol	NN	alcohol
,	,	,
and	CC	and
hypersensitivity	NN	hypersensitivity
reactions	NNS	reaction
,	,	,
as	RB	as
well	RB	well
as	IN	as
evidence	NN	evidence
of	IN	of
tumorigenicity	NN	tumorigenicity
in	IN	in
rodent	NN	rodent
studies	NNS	study
.	.	.
</s>
<s type="decl">
Furthermore	RB	furthermore
,	,	,
<hi rend="italic">
G.	NNP	G.
lamblia	NNP	lamblia
</hi>
resistance	NN	resistance
to	IN	to
this	DT	this
drug	NN	drug
has	VBZ	have
also	RB	also
been	VBN	be
reported	VBN	report
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
research	NN	research
focusing	VBG	focus
on	IN	on
the	DT	the
development	NN	development
of	IN	of
novel	JJ	novel
,	,	,
alternative	JJ	alternative
drugs	NNS	drug
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
giardiasis	NN	giardiasis
is	VBZ	be
highly	RB	highly
desirable	JJ	desirable
.	.	.
</s>
<s type="decl">
In	IN	in
view	NN	view
of	IN	of
these	DT	this
considerations	NNS	consideration
,	,	,
researchers	NNS	researcher
have	VBP	have
designed	VBN	design
and	CC	and
synthesized	VBN	synthesize
some	DT	some
novel	JJ	novel
molecules	NNS	molecule
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
giardiasis	NN	giardiasis
,	,	,
their	PRP$	their
results	NNS	result
are	VBP	be
summarized	VBN	summarize
in	IN	in
Table	NNP	Table
1	CD	1
.	.	.
</s>
</p>
</text>